2. Search Result
Search Result
Results for "

Hep3B

" in MedChemExpress (MCE) Product Catalog:

90

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

2

Inhibitory Antibodies

20

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10331
    Regorafenib
    Maximum Cited Publications
    87 Publications Verification

    BAY 73-4506

    		 VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie Cancer
    Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .
    Regorafenib
  • HY-101513
    eIF4A3-IN-1
    4 Publications Verification

    		 Eukaryotic Initiation Factor (eIF) Neurological Disease Cancer
    eIF4A3-IN-1 is a selective eIF4A3 inhibitor (IC50: 0.26 μM; Kd: 0.043 μM) with cellular nonsense-mediated RNA decay (NMD) inhibitory activity. eIF4A3-IN-1 can specifically bind to the non-ATP binding site of eIF4A3. eIF4A3-IN-1 has anti-tumor and analgesic activities [3].
    eIF4A3-IN-1
  • HY-N0316
    Mollugin
    2 Publications Verification

    		 JAK NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc Cancer
    Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway [3].
    Mollugin
  • HY-101568
    Roblitinib
    5+ Cited Publications

    FGF-401

    		 FGFR Cancer
    Roblitinib (FGF-401) is an orally active and highly selective FGFR4 inhibitor with an IC50 of 1.9 nM . Roblitinib has antitumor activity .
    Roblitinib
  • HY-N0732
    Jolkinolide B
    1 Publications Verification

    		 IAP Akt Caspase NF-κB TGF-beta/Smad JAK Bacterial Apoptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis [3] .
    Jolkinolide B
  • HY-10331A
    Regorafenib monohydrate
    Maximum Cited Publications
    87 Publications Verification

    BAY 73-4506 monohydrate

    		 VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie Cancer
    Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .
    Regorafenib monohydrate
  • HY-N0699
    Daphnoretin
    3 Publications Verification

    Dephnoretin; Thymelol

    		 PKC Influenza Virus NOD-like Receptor (NLR) Apoptosis HBV JNK PI3K Akt CDK Caspase Bcl-2 Family Infection Inflammation/Immunology Cancer
    Daphnoretin (Dephnoretin; Thymelol) is a protein kinase C (PKC) activator that inhibits the expression of hepatitis B virus (HBV) surface antigen (HBsAg) and exhibits antiviral activity. Daphnoretin exerts its antitumor effects by inhibiting the activation of the PI3K/AKT signaling pathway and triggers the mitochondrial apoptosis pathway. Daphnoretin alleviates chondrocyte apoptosis and inflammatory responses by inhibiting endoplasmic reticulum stress and activation of the NLRP3 inflammasome. Daphnoretin regulates the differentiation and maturation of dendritic cells, inhibits their immunostimulatory function by downregulating the phosphorylation level of JNK, and thus exerts a protective effect in skin graft rejection [3] .
    Daphnoretin
  • HY-131183
    PROTAC PD-1/PD-L1 degrader-1

    		PROTACs PD-1/PD-L1 Inflammation/Immunology
    PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .
    PROTAC PD-1/PD-L1 degrader-1
  • HY-107781
    PAT-505

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PAT-505 is a potent, selective, noncompetitive and orally available autotaxin inhibitor, with an IC50 of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma.
    PAT-505
  • HY-148049
    TT3

    		Liposome Others
    TT3 is an ionizable lipid-like material and a lipid nanoparticle (LLNs)-based mRNA delivery vector. TT3 exhibits liver and spleen specificity and excellent delivery efficiency .
    TT3
  • HY-N8439
    Questiomycin A

    Phx-3

    		 HSP Bacterial Antibiotic Infection Cancer
    Questiomycin A (Phx-3) is a GRP78 (cytoprotective endoplasmic reticulum chaperone) degrader and enhances the anticancer activity of Sorafenib. Questiomycin A is also an antimicrobial/antibiotic that can be obtained from the metabolite of Pseudomonas chlororaphis HT66. Questiomycin A can be used in research on biological control of cancer and plant diseases .
    Questiomycin A
  • HY-153967
    BLU0588
    2 Publications Verification

    		 PKA Cancer
    BLU0588 is an orally active, potent and selective PRKACA (protein kinase cAMP-activated catalytic subunit alpha) kinase inhibitor, with an IC50 of 1 nM and dissociation constant (Kd) of 4 nM. BLU0588 can be used for fibrolamellar carcinoma (FLC) research .
    BLU0588
  • HY-16350
    BOLD-100
    1 Publications Verification

    NKP-1339; IT-139; KP-1339

    		 DNA/RNA Synthesis Apoptosis Cancer
    BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu .
    BOLD-100
  • HY-N16040
    DMG-pSar25

    		Liposome Others
    DMG-pSar25 is a double lipid-tailed polysarcosine lipid with 25 sarcosine moieties, serving as a PEG lipid substitute in lipid nanoparticle formulations for mRNA delivery. DMG-pSar25 supports mRNA delivery in lipid nanoparticle formulations .
    DMG-pSar25
  • HY-N2445
    Flavokawain C
    4 Publications Verification

    		 Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK Cancer
    Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer [3] .
    Flavokawain C
  • HY-139287
    M1002
    2 Publications Verification

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors .
    M1002
  • HY-108868
    Mersalyl

    Salirgan; Salurin; Salyrgan

    		 HIF/HIF Prolyl-Hydroxylase VEGFR Metabolic Disease
    Mersalyl (Salirgan) is a potent vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (HIF-1) inducer. Mersalyl induces VEGF and ENO1 mRNA expression. Mersalyl shows diuresis effects [3].
    Mersalyl
  • HY-115449
    Chromeceptin
    2 Publications Verification

    94G6

    		 IGF-1R Akt mTOR Cancer
    Chromeceptin (94G6) is an IGF signaling pathway inhibitor. Chromeceptin suppresses IGF2 expression at mRNA and protein levels in hepatocyte and HCC cells. Chromeceptin inhibits the phosphorylation levels of AKT and mTOR .
    Chromeceptin
  • HY-P990841
    Anti-pan-Glypican Antibody (HS20)

    		Glycoprotein VI Cancer
    Anti-pan-Glypican Antibody (HS20) is a kind of human IgG1 κ human antibody, targeting to human pan-Glypican. Anti-pan-Glypican Antibody (HS20) can neutralize the heparan sulfate (HS) chains on GPC3 thereby disrupting the Wnt3a-GPC3 interactions leading to blockade of the Wnt3a/β-catenin signaling. Anti-pan-Glypican Antibody (HS20) can be used for the research of cancer, such as hepatocellular carcinoma (HCC) .
    Anti-pan-Glypican Antibody (HS20)
  • HY-W011434
    Triglycidyl isocyanurate

    TGIC

    		 MDM-2/p53 Apoptosis Inflammation/Immunology Cancer
    Triglycidyl isocyanurate (TGIC; Teroxirone) is a triazene triepoxide with antiangiogenic and antineoplastic activities. Triglycidyl isocyanurate inhibits the growth of non-small-cell-lung cancer cells via?p53 activation. Triglycidyl isocyanurate induces cell apoptosis. Triglycidyl isocyanurate can be used for cancer research .
    Triglycidyl isocyanurate
  • HY-144999
    LEB-03-146

    		Wee1 Cancer
    LEB-03-146 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through a PEG2 linker. LEB-03-146 shows significant WEE1 stabilization in HEP3B hepatoma cancer cells .
    LEB-03-146
  • HY-159120
    ZG-2291

    		HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    ZG-2291 is a selective inhibitor targeting FIH (Factor Inhibiting HIF) with oral activity. By binding to FIH, ZG-2291 promotes a conformational flip of a catalytically important tyrosine, enabling selective inhibition of FIH without affecting other 2OG oxygenases in the JmjC subfamily. ZG-2291k enhances thermogenesis in ob/ob mice and improves obesity-related symptoms and metabolic dysfunctions. ZG-2291 holds promise for research in the field of obesity-related diseases .
    ZG-2291
  • HY-117720
    OSU-2S

    		PKC Apoptosis Cancer
    OSU-2S is a potent PKCδ activator. OSU-2S inhibits cell proliferation and migration. OSU-2S decreases the expression of p-ERK1/2, increases the expression of PKCδ (38 kDa) when combined with Sorafenib (HY-10201). OSU-2S induces Apoptosis. OSU-2S slao is a non-immunosuppressive analogue of FTY720. OSU-2S shows anticancer activity .
    OSU-2S
  • HY-W599279
    ABS-752

    		Molecular Glues NEKs Cancer
    ABS-752 is a potent and orally active GSPT1 and NEK7 molecular glue degrader. ABS-752 shows cytotoxicity. ABS-752 decreases the protein expression of GSPT1 and SALL4, NEK7. ABS-752 is a prodrug activated by the monoamine oxidase, VAP-1, to an aldehyde intermediate and subsequently to the active molecule, ABT-002 (HY-175283). ABS-752 has the potential for the research of hepatocellular carcinoma .
    ABS-752
  • HY-168533
    ZG-2305

    		HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    ZG-2305 is a potent, orally active and selective factor inhibiting hypoxia-inducible factor (FIH) inhibitor with Ki values of 79.6, 2786 nM for FIH, PHD2, respectively. ZG-2305 increases the expression of EGLN3 gene. ZG-2305 decreases the cellular triglycerides levels and reduces lipid accumulation. ZG-2305 has the potential for the research of obesity and fatty liver disease .
    ZG-2305
  • HY-B1272A
    Desipramine

    		Adrenergic Receptor ERK JNK p38 MAPK NF-κB AP-1 Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism TNF Receptor Neurological Disease Inflammation/Immunology Cancer
    Desipramine is a first-generation tricyclic antidepressant. Desipramine selectively binds to norepinephrine transporter and blocks neuronal norepinephrine reuptake. Desipramine activates MAPK signaling via ERK1/2, JNK, and p38, represses NF-κB and AP-1 activity, and induces apoptosis via ROS elevation, mitochondrial membrane potential reduction, and intracellular calcium increase. Desipramine also shows anyi-inflammatory activity, inhibiting TNF-α production. Desipramine can be used for the research of hepatocellular cancer, inflammation, and neurological diseases [3] .
    Desipramine
  • HY-P10323
    T7 Peptide

    Tumstatin (74-98), human

    		 Integrin FAK mTOR Apoptosis Cancer
    T7 Peptide is a protein synthesis inhibitor and anti-angiogenic agent, with a Kd of 10 nM for human transferrin receptor. T7 Peptide inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma [3] .
    T7 Peptide
  • HY-143342
    LEB-03-144

    		Wee1 Cancer
    LEB-03-144 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through a C3 alkyl linker. LEB-03-144 shows significant WEE1 stabilization in HEP3B hepatoma cancer cells .
    LEB-03-144
  • HY-134008
    Protoapigenone

    		Apoptosis Bcl-2 Family Caspase Cancer
    Protoapigenone is an antineoplastic agent isolated from ferns. Protoapigenone has significant inhibitory activity against Hep G2, Hep 3B, MCF-7, A549 and MDAMB-231, with IC50s values of 1.60, 0.23, 0.78, 3.88 and 0.27 μg/mL respectively .
    Protoapigenone
  • HY-146350
    TrxR-IN-4

    		TrxR Reactive Oxygen Species (ROS) Apoptosis Cancer
    TrxR-IN-4 is a thioredoxin reductase (TrxR) inhibitor with a rat IC50 of 0.37 μM. TrxR-IN-4 inhibits TrxR activity, elevates reactive oxygen species (ROS) and induces apoptosis. TrxR-IN-4 mediates endoplasmic reticulum stress and induces mitochondrial dysfunction. TrxR-IN-4 can be used for the research of hepatocellular carcinoma .
    TrxR-IN-4
  • HY-N1833
    3'-Geranyl-3-prenyl-2',4',5,7-tetrahydroxyflavone

    		Others Cancer
    3'-Geranyl-3-prenyl-2',4',5,7-tetrahydroxyflavone displays cytotoxicity of 1.32, 3.92 and 5.22 μm against the human cervical carcinoma HeLa, human breast carcinoma MCF-7, and human hepatocarcinoma Hep3B cells .
    3'-Geranyl-3-prenyl-2',4',5,7-tetrahydroxyflavone
  • HY-W242821
    Methyl 3,4-dimethoxycinnamate

    		Fungal Cancer
    Methyl 3,4-dimethoxycinnamate is an inhibitor of uredospore germination. Methyl 3,4-dimethoxycinnamate also inhibits global DNA methylation in in Hep3B cells .
    Methyl 3,4-dimethoxycinnamate
  • HY-N10417
    Apoptosis inducer 5

    		Apoptosis Autophagy Cancer
    Apoptosis inducer 5 (compound 1b) is a lignan enantiomer that can be found in Crataegus pinnatifida. Apoptosis inducer 5 exhibits cytotoxic effect via apoptosis and autophagy in Hep3B cells .
    Apoptosis inducer 5
  • HY-147039
    BOLD-100 free base

    NKP-1339 free base; IT-139 free base; KP-1339 free base

    		 HSP Autophagy Cancer
    BOLD-100 (NKP-1339; IT-139) free base is a ruthenium-based anticancer agent. BOLD-100 free base also is an inhibitor of stress-induced GRP78 upregulation, disrupting endoplasmic reticulum (ER) homeostasis and inducing ER stress and unfolded protein response (UPR). BOLD-100 free base interferes with the complex interplay between ER-stress response, lysosome dynamics, and autophagy execution .
    BOLD-100 free base
  • HY-162657
    AChE-IN-74

    		Cholinesterase (ChE) Cancer
    AChE-IN-74 (Compound 10) is a modulator for cholinesterase. AChE-IN-74 inhibits the proliferation of liver cancer cell Hep3B and SkHep1 with IC50 of 3.6 and 19.9 μM. AChE-IN-74 exhibits a low embryonic toxicity in zebrafish models (10-15 μM) .
    AChE-IN-74
  • HY-161648
    Anticancer agent 222

    		Drug Derivative Cancer
    Anticancer agent 222 (Compound 19) is an orally active anticancer agent that exhibits significant anticancer activity against Huh7, FOCUS, SNU475, SNU182, HepG2, and Hep3B cells (IC50 = 2.9–9.3 μM) .
    Anticancer agent 222
  • HY-161617
    LASSBio-2052

    		DNA/RNA Synthesis Apoptosis Cancer
    LASSBio-2052 is a derivative of N-acylhydrazone with antitumor activity against hepatocellular carcinoma (HCC). LASSBio-2052 inhibits HCC cells HepG2 and Hep3B, with IC50 of 18 and 41 μM. LASSBio-2052 arrests the cell cycle at G2/M phase, through downregulation of FOXM1. LASSBio-2052 induces apoptosis in HCC cells .
    LASSBio-2052
  • HY-P2783
    Destruxin B2

    		HBV Infection
    Destruxin B2 (compound 5) is a natural depsipeptide that can be inhibits hepatitis B surface antigen (HBsAg) secretion in Hep3B cells with an IC50 1.30 μM .
    Destruxin B2
  • HY-156527
    PHD-IN-2

    		HIF/HIF Prolyl-Hydroxylase Cancer
    PHD-IN-2 (Compound 91) is a PHD antagonist (IC50: < 5 nM). PHD-IN-2 induces erythropoietin synthesis in HEP3B cells (EC50: <2.5 μM). PHD-IN-2 can be used for research of cardiovascular disorders, metabolic disorders, hematological disorders, pulmonary disorders, kidney disorders, liver disorders, wound healing disorders, and cancer .
    PHD-IN-2
  • HY-156130
    Menin-MLL inhibitor 29

    		Epigenetic Reader Domain Cancer
    Menin-MLL inhibitor 29 (Compound C1) is a Menin-MLL PPI inhibitor. Menin-MLL inhibitor 29 binds to Menin with a KD value of 138 nM, and inhibits the binding of Menin to MBM1 (Menin-binding motif 1) with an IC50 value of 46 nM. Menin-MLL inhibitor 29 inhibits HepG2 and Hep3B hepatoma cell proliferation (IC50s: 0.31 μM and 0.71 μM). Menin-MLL inhibitor 29 inhibits tumor growth .
    Menin-MLL inhibitor 29
  • HY-163839
    DS-1093a

    		HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    DS-1093a is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor, with an EC50 of 0.49 μM in Hep3B cell EPO production. DS-1093a can be used in the research of renal anemia .
    DS-1093a
  • HY-156526
    PHD-IN-1

    		HIF/HIF Prolyl-Hydroxylase Others
    PHD-IN-1 (compound 80) is a potent inhibitor of PHD2，with an IC50 value of ≤5 nM. PHD-IN-1 shows EC50s of 2.5 μM in EPO Elisa assay both in Caco2-HIFla-HiBiT-clone-1 cells and Hep3B cells，respectively .
    PHD-IN-1
  • HY-145836
    FGFR4-IN-8

    		FGFR Cancer
    FGFR4-IN-8 (Compound 7v) is an ATP-competitive, highly selective covalent inhibitor of wild-type and gatekeeper mutant FGFR4. FGFR4-IN-8 exhibits excellent potency against FGFR4, FGFR4 V550L, FGFR4 V550M and FGFR4 C552S with IC50s of 0.5, 0.25, 1.6, 931 nM, respectively. FGFR4-IN-8 exhibits potent antiproliferative activity against Hep3B hepatocellular carcinoma cells with the IC50 value of 29 nM. FGFR4-IN-8 demonstrates modest in vivo antitumor efficacy in nude mice bearing the Huh-7 xenograft model .
    FGFR4-IN-8
  • HY-175553
    VEGFR-2-IN-72

    		VEGFR Apoptosis Cancer
    VEGFR-2-IN-72 is a selective VEGFR-2 inhibitor with an IC50 of 22.2 nM. VEGFR-2-IN-72 exhibits anticancer activity against HepG2 and Hep3B human HCC cell lines with IC50s of 15.7 and 2.4 μM. VEGFR-2-IN-72 can cause a mild blockage of the cell cycle and induce cell aopoptosis. VEGFR-2-IN-72 can used for the study of hepatocellular carcinoma (HCC) .
    VEGFR-2-IN-72
  • HY-141625
    TRC160334

    		HIF/HIF Prolyl-Hydroxylase Others
    TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury .
    TRC160334
  • HY-168114
    Multi-kinase inhibitor 3

    		FLT3 PDGFR VEGFR Cancer
    Multi-kinase inhibitor 3 (compound 12) is a potent and orally active multikinase inhibitor with IC50 values of 1.59, 1.23, 1.19, 0.59, 0.22, 1.15 nM for FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, PDGFRβ, respectively. Multi-kinase inhibitor 3 shows antiproliferative activity. Multi-kinase inhibitor 3 shows anticancer activity .
    Multi-kinase inhibitor 3
  • HY-18203
    HBF-0079

    		Apoptosis Akt mTOR Cancer
    HBF-0079 is a selective anti-hepatocellular carcinoma agent. HBF-0079 induces cell cycle arrest and Apoptosis. HBF-0079 modulates cell-growth and anti-apoptotic signaling through AKT and mTOR. HBF-0079 exhibits antitumor activity against hepatocellular carcinoma .
    HBF-0079
  • HY-168115
    Multi-kinase inhibitor 4

    		FLT3 PDGFR Cancer
    Multi-kinase inhibitor 4 (compound 14) is an orally active inhibitor of FLT1, KDR, FLT3, FLT4, PDGFRα, PDGFRβ, with IC50s of 1.97 nM, 1.04 nM, 0.33 nM, 1.44 nM, 0.18 nM, 0.89 nM. Multi-kinase inhibitor 4 plays an important role in cancer research .
    Multi-kinase inhibitor 4
  • HY-10331B
    Regorafenib mesylate

    BAY 73-4506 mesylate

    		 VEGFR PDGFR RET Raf c-Kit FGFR Autophagy Tie Cancer
    Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity .
    Regorafenib mesylate
  • HY-10331AR
    Regorafenib monohydrate (Standard)

    BAY 73-4506 monohydrate (Standard)

    		 Reference Standards VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie Cancer
    Regorafenib (monohydrate) (Standard) is the analytical standard of Regorafenib (monohydrate). This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .
    Regorafenib monohydrate (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: